ReP USP - Resultado da busca

Artigo de periodico
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia (2014)
Lima, Luciene Terezinha de; Vivona, Douglas; Bueno, Carolina Tosin; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Castro, Fabíola Attié de; Chauffaille, Maria de Lourdes L. F; Zanichelli, Maria Aparecida; Chiattone, Carlos Sérgio; Hungria, Vania Tietsche de Moraes; Guerra-Shinohara, Elvira Maria
Source: Medical Oncology. Unidades: FCF, FCFRP
Subjects: LEUCEMIA MIELOIDE, POLIMORFISMO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Luciene Terezinha de et al. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Medical Oncology, v. 31, p. 1-11, 2014Tradução . . Disponível em: https://doi.org/10.1007/s12032-014-0851-5. Acesso em: 28 jun. 2024.
APA
Lima, L. T. de, Vivona, D., Bueno, C. T., Hirata, R. D. C., Hirata, M. H., Luchessi, A. D., et al. (2014). Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia. Medical Oncology, 31, 1-11. doi:10.1007/s12032-014-0851-5
NLM
Lima LT de, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Castro FA de, Chauffaille M de LLF, Zanichelli MA, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia [Internet]. Medical Oncology. 2014 ; 31 1-11.[citado 2024 jun. 28 ] Available from: https://doi.org/10.1007/s12032-014-0851-5
Vancouver
Lima LT de, Vivona D, Bueno CT, Hirata RDC, Hirata MH, Luchessi AD, Castro FA de, Chauffaille M de LLF, Zanichelli MA, Chiattone CS, Hungria VT de M, Guerra-Shinohara EM. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia [Internet]. Medical Oncology. 2014 ; 31 1-11.[citado 2024 jun. 28 ] Available from: https://doi.org/10.1007/s12032-014-0851-5
Trabalho de evento-resumo periodico
Imatinib response is influenced by abc and slc transporters polymorphisms in chronic myeloid leukemia patients (2012)
Boacnin, Marina do Rosário; Bueno, Carolina Tosin; Lima, Luciene Terezinha de; Vivona, Douglas; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Ducati, André; Zanichelli, Luchessi Maria Aparecida; Chittone, Carlos Sergio; Guerra-Shinohara, Elvira Maria
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Science and Technology Meeting. Unidade: FCF
Subjects: POLIMORFISMO, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOACNIN, Marina do Rosário et al. Imatinib response is influenced by abc and slc transporters polymorphisms in chronic myeloid leukemia patients. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 28 jun. 2024. , 2012
APA
Boacnin, M. do R., Bueno, C. T., Lima, L. T. de, Vivona, D., Hirata, R. D. C., Hirata, M. H., et al. (2012). Imatinib response is influenced by abc and slc transporters polymorphisms in chronic myeloid leukemia patients. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Boacnin M do R, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Ducati A, Zanichelli LMA, Chittone CS, Guerra-Shinohara EM. Imatinib response is influenced by abc and slc transporters polymorphisms in chronic myeloid leukemia patients. Brazilian Journal of Pharmaceutical Sciences. 2012 ; 48 88 res. FCF172.[citado 2024 jun. 28 ]
Vancouver
Boacnin M do R, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Ducati A, Zanichelli LMA, Chittone CS, Guerra-Shinohara EM. Imatinib response is influenced by abc and slc transporters polymorphisms in chronic myeloid leukemia patients. Brazilian Journal of Pharmaceutical Sciences. 2012 ; 48 88 res. FCF172.[citado 2024 jun. 28 ]
Trabalho de evento-resumo
SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients (2011)
Guerra-Shinohara, Elvira Maria ; Bueno, Carolina Tosin; Lima, Luciene Terezinha de; Vivona, Douglas; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Chiattone, Carlos Sérgio; Zanichelli, Maria Aparecida
Source: Abstracts. Conference titles: Annual Congress of the European Hematology Association (EHA). Unidade: FCF
Subjects: POLIMORFISMO, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUERRA-SHINOHARA, Elvira Maria et al. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. 2011, Anais.. Hague: European Hematology Association (EHA), 2011. . Acesso em: 28 jun. 2024.
APA
Guerra-Shinohara, E. M., Bueno, C. T., Lima, L. T. de, Vivona, D., Hirata, R. D. C., Hirata, M. H., et al. (2011). SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. In Abstracts. Hague: European Hematology Association (EHA).
NLM
Guerra-Shinohara EM, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Luchessi AD, Chiattone CS, Zanichelli MA. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. Abstracts. 2011 ;[citado 2024 jun. 28 ]
Vancouver
Guerra-Shinohara EM, Bueno CT, Lima LT de, Vivona D, Hirata RDC, Hirata MH, Luchessi AD, Chiattone CS, Zanichelli MA. SLC22A1 polymorphisms are not associated with cytogenetic and molecular response to imatinib mesylate in chronic myelogenous leukemia patients. Abstracts. 2011 ;[citado 2024 jun. 28 ]
Trabalho de evento-resumo
Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib (2011)
Guerra-Shinohara, Elvira Maria ; Vivona, Douglas; Bueno, Carolina Tosin; Lima, Luciene Terezinha de; Hirata, Rosario Dominguez Crespo ; Hirata, Mario Hiroyuki ; Luchessi, André Ducati; Zanichelli, Maria Aparecida; Chiattone, Carlos Sérgio
Source: Abstracts. Conference titles: Annual Congress of the European Hematology Association (EHA). Unidade: FCF
Subjects: POLIMORFISMO, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUERRA-SHINOHARA, Elvira Maria et al. Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. 2011, Anais.. Hague: European Hematology Association (EHA), 2011. . Acesso em: 28 jun. 2024.
APA
Guerra-Shinohara, E. M., Vivona, D., Bueno, C. T., Lima, L. T. de, Hirata, R. D. C., Hirata, M. H., et al. (2011). Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. In Abstracts. Hague: European Hematology Association (EHA).
NLM
Guerra-Shinohara EM, Vivona D, Bueno CT, Lima LT de, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS. Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Abstracts. 2011 ;[citado 2024 jun. 28 ]
Vancouver
Guerra-Shinohara EM, Vivona D, Bueno CT, Lima LT de, Hirata RDC, Hirata MH, Luchessi AD, Zanichelli MA, Chiattone CS. Haplotype for polymorphisms C1236T, C3435T and C2677T/A in MDR1 gene is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Abstracts. 2011 ;[citado 2024 jun. 28 ]
Trabalho de evento-resumo periodico
Association between the C1236T, C3435T and G2677T/A polymorphisms in the ABCB1 gene and response markers for imatinib mesylate in patients with chronic myeloid leukemia (2010)
Bueno, Carolina Tosin; Vivona, Douglas; Lima, Luciene Terezinha de; Hirata, Mario Hiroyuki ; Hirata, Rosario Dominguez Crespo ; Luchessi, André Ducati; Chiattone, Carlos Sérgio; Zanichelli, Maria Aparecida; Guerra-Shinohara, Elvira Maria
Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Science and Pharmaceutical Technology Meeting of the Pharmaceutical Sciences Faculty of the University of São Paulo. Unidade: FCF
Subjects: POLIMORFISMO, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUENO, Carolina Tosin et al. Association between the C1236T, C3435T and G2677T/A polymorphisms in the ABCB1 gene and response markers for imatinib mesylate in patients with chronic myeloid leukemia. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 28 jun. 2024. , 2010
APA
Bueno, C. T., Vivona, D., Lima, L. T. de, Hirata, M. H., Hirata, R. D. C., Luchessi, A. D., et al. (2010). Association between the C1236T, C3435T and G2677T/A polymorphisms in the ABCB1 gene and response markers for imatinib mesylate in patients with chronic myeloid leukemia. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.
NLM
Bueno CT, Vivona D, Lima LT de, Hirata MH, Hirata RDC, Luchessi AD, Chiattone CS, Zanichelli MA, Guerra-Shinohara EM. Association between the C1236T, C3435T and G2677T/A polymorphisms in the ABCB1 gene and response markers for imatinib mesylate in patients with chronic myeloid leukemia. Brazilian Journal of Pharmaceutical Sciences. 2010 ; 46 85 res. FCF165.[citado 2024 jun. 28 ]
Vancouver
Bueno CT, Vivona D, Lima LT de, Hirata MH, Hirata RDC, Luchessi AD, Chiattone CS, Zanichelli MA, Guerra-Shinohara EM. Association between the C1236T, C3435T and G2677T/A polymorphisms in the ABCB1 gene and response markers for imatinib mesylate in patients with chronic myeloid leukemia. Brazilian Journal of Pharmaceutical Sciences. 2010 ; 46 85 res. FCF165.[citado 2024 jun. 28 ]

USP Schools

ReP

Filtros

Authors